Jefferson (GA)
{name}
{subtitle}
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~15 mi. (Braselton, Georgia, +825 more cities)
facility
Northeast Georgia Medical Center Braselton
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
city
~15 mi. (Braselton, Georgia, +954 more cities)
facility
Northeast Georgia Medical Center Braselton
condition
Non-Small Cell Lung Carcinoma
drug
crizotinib, +4 more drugs
drug type
chemotherapy, +2 more types
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
city
~15 mi. (Braselton, Georgia, +577 more cities)
facility
Northeast Georgia Medical Center Braselton
condition
Non-Small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~21 mi. (Athens, Georgia, +144 more cities)
facility
University Cancer & Blood Center, LLC ( Site 0057)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~21 mi. (Athens, Georgia, +226 more cities)
facility
University Cancer & Blood Center, LLC
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
condition
Non-Squamous Non-Small Cell Lung Carcinoma
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~21 mi. (Athens, Georgia, +247 more cities)
facility
University Cancer Blood Ctr
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~21 mi. (Athens, Georgia, +89 more cities)
facility
University Cancer & Blood Center, LLC ( Site 0032)
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
city
~21 mi. (Athens, Georgia, +172 more cities)
facility
University Cancer Blood Ctr
condition
Urothelial Carcinoma
drug
cisplatin, +3 more drugs
drug type
chemotherapy, +1 more type